Journals / The European Research Journal / 2019 / Cilt: 5 - Sayı: 3

Comparison of laboratory and imaging methods associated with bone metabolism in patients with or without renal failure under the age of 45 years with elevated parathyroid hormone levels

Pages
515–521
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Except Z score at Ward’s triangle, all of the T and Z scores at lomber, femur neck, trochanteric,and intertrochanteric areas were found significantly lower in patients with chronic kidney disease compared tothose without (p < 0.001).Conclusion: Dual energy X-ray absorptiometry seemed to be a reliable method for detection of osteoporosisin premenopausal female and male patients younger than 45 years of age with or without renal failure withelevated parathyroid hormone levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Although bone biopsy is considered the gold standard for the definitive diagnosis of renalosteodystrophy; it is not suitable for routine clinical practice due to its invasive nature.
📊
Key Findings & Data:The present study wasaimed to evaluate and compare the bone mineral status using dual energy X-ray absorptiometry of patientswith or without chronic kidney disease in young population with elevated parathyroid hormone levels.Methods: This was a single center, cross-sectional, retrospective study conducted in patients younger than 45years of age.
💡
Conclusion & Impact:Except Z score at Ward’s triangle, all of the T and Z scores at lomber, femur neck, trochanteric,and intertrochanteric areas were found significantly lower in patients with chronic kidney disease compared tothose without (p < 0.001).Conclusion: Dual energy X-ray absorptiometry seemed to be a reliable method for detection of osteoporosisin premenopausal female and male patients younger than 45 years of age with or without renal failure withelevated parathyroid hormone levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Although bone biopsy is considered the gold standard for the definitive diagnosis of renalosteodystrophy; it is not suitable for routine clinical practice due to its invasive nature. The present study wasaimed to evaluate and compare the bone mineral status using dual energy X-ray absorptiometry of patientswith or without chronic kidney disease in young population with elevated parathyroid hormone levels.Methods: This was a single center, cross-sectional, retrospective study conducted in patients younger than 45years of age. The study was performed in the outpatient clinic of a university hospital. Patients with elevatedparathyroid hormone levels were included.Results: Among them, 29 had renal insufficiency, 158 had normal renal function. Measured bone mineraldensity with dual energy X-ray absorptiometry and laboratory values were collected from patient files. Theprimary end point was to assess the efficiacy of dual energy X-ray absorptiometry in patients with or withoutrenal failure. Except Z score at Ward’s triangle, all of the T and Z scores at lomber, femur neck, trochanteric,and intertrochanteric areas were found significantly lower in patients with chronic kidney disease compared tothose without (p < 0.001).Conclusion: Dual energy X-ray absorptiometry seemed to be a reliable method for detection of osteoporosisin premenopausal female and male patients younger than 45 years of age with or without renal failure withelevated parathyroid hormone levels.

🔖

Cite This Article

Ersoy, A., Özkaya, G., Peynirci, H., Ersoy, C., Sayılar, E. I., Gürsoy, V., Girgin, A., Aşık, M. A., Gültepe, A. (2022). Comparison of laboratory and imaging methods associated with bone metabolism in patients with or without renal failure under the age of 45 years with elevated parathyroid hormone levels. The European Research Journal, Cilt: 5 - Sayı: 3, 515–521. https://ajindex.com/articles/597602

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004;66:1310-4
  2. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med 2018;168:422-30
  3. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 Suppl):S505-11
  4. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011;26:1368-76
  5. Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008;3 Suppl 3:S140-50
  6. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000;54:218-26
  7. Khan MI, Syed GM, Khan AI, Sirwal IA, Anwar SK, Al-Oufi AR, et al. Mean bone mineral density and frequency of occurrence of osteopenia and osteoporosis in patients on hemodialysis: a single-center study. Saudi J Kidney Dis Transpl 2014;25:38-43
  8. Jannot M, Mac-Way F, Lapierre V, Lafage-Proust MH. The use of bone mineral density measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed microtomography in chronic kidney disease. J Nephrol 2017;30:635-43
  9. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87
  10. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
  11. O'Connor KM. Evaluation and treatment of osteoporosis. Med Clin North Am 2016;100:807-26
  12. Lima GA, Paranhos Neto Fde P, Pereira GR, Gomes CP, Farias ML. Osteoporosis management in patient with renal function impairment. Arq Bras Endocrinol Metabol 2014;58:530-9
  13. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 2012;27:727-33
  14. Kovesdy CY, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbon